32 results about "CYP1B1" patented technology

The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., beta-2 microgobulin (B2M) and cytochrome p450 1B1 (CYP1B1). The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. For example, over-expression of B2M and under-expression of CYP1B1 can be indicative of the likelihood a subject has squamous cell carcinoma. Also, over-expression of B2M and over-expression of CYP1B1 can be indicative of the likelihood a subject has a precancerous squamous cell disorder. The expression levels of B2M and CYP1B1 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.

The invention discloses a plasticizer tracking biomarker, a plasticizer tracking genetic chip, and a plasticizer tracking biomarker confirmation method. The biomarker found through the confirmation method is one or more of human gene / protein clusters composed of PPARG, CASP3, PPARA, NR1I2, ESR1, AR, CYP1B1, ABCB1, CYP1A1, VEGFA, ESR2, PPARD, LAMP3, BAX, BCL2, CDO1, CELSR2, CSNK1A1, CYP3A4, MAPK1, MAPK3, MYC, NCOA1, PAPSS1, PAPSS2, SUOX, SLC5A5, AKR1C1, IL4, INHA and PCNA, and is suitable for detecting that whether there is pollution of plasticizers, such as phthalate and the like, in a human body or not.

Systems and methods for determining the prognosis of a patient having CYP1B1-mediated lung cancer and for diagnosing a risk of developing CYP1B1-mediated lung cancer are provided. The systems and methods comprise determinations of the concentration of estrogen metabolites in the lung tissue or a proxy thereof, or polymorphisms in the gene encoding the CYP1B1 protein, which metabolite concentrations or CYP1B1 polymorphisms are associated with a probability of surviving and / or a risk of developing lung cancer.

Inhibitors of the enzyme cytochrome P450 (CYP), including 1B1 (CYP1B1), 1A1 (CYP1A1) and 19A1 (CYP19A1) are provided, and are useful in medical applications. Disclosed are highly potent and selective compounds that can be used in chemoprevention to ameliorate malignant changes induced by CYP, or to aid in treatment, including restoration of chemotherapeutic efficacy.

The invention discloses a radioactive drug targeting CYP1B1 enzyme 18 F-labeled probe precursors; the probe precursors include affinity ligands that can be combined with CYP1B1 enzymes, and can be used for 18 The chelating group of F rapid label and the linking chain that is used to connect part and chelating group; The linking chain comprises multiple ethylene glycol fragments; The affinity part is α-naphthoflavone derivative, available At 18 The chelating group of F rapid labeling is 1,4,7-triazacyclononane-1,4-diacetic acid molecule. The present invention is a kind of CYP1B1 enzyme that can be combined with tumor-specific expression, and can be used for 18 F-labeled molecular probe precursor, after radiolabeling, can show the level of CYP1B1 enzyme in the tumor in PET imaging to visualize the tumor. The invention will effectively promote the application of molecular imaging technology in tumor diagnosis.

The present invention relates to the application of miRNA-27b in anti-tumor drug resistance. Specifically, the present invention studies tumor tissues of tumor patients and conducts large-scale screening of human miRNA libraries through high-throughput microRNA chips. Among a large number of microRNAs, it is found that miR-27b is generally down-regulated in tumors, and miR-27b family members It can improve the sensitivity of tumor cells to anti-tumor drugs. The present invention also finds that miR-27b targets genes such as p53 and CYP1B1 in the tumor drug resistance signaling pathway; promoting p53 and inhibiting CYP1B1 expression can improve the sensitivity of tumors to anti-tumor drugs.

An in vitro method of determining the type of a fibroepithelial tumour of the breast in a biological sample is provided. The method comprises the steps of obtaining an expression profile of one or more genes selected from the group consisting of PRAME, ADH1 B, CTHRC1, NPTX2, NEFL, ABCA8, DAPL1, TP63_v2, COL17A1, GCNT2, CCL19, MMP3, FN1, TRERF1, TRIM29, TESC, KIF20A, UHRF1, HEPACAM2, APOD, SERHL2. KIF15, HOXD13, GAGE2B, CALML5, C2orf40, ADH1C, CYP1B1, SPAG11B, GRB7, UBE2C, SYNGAP1, TP63_v1, LAMB1, OR5P3, SPC25, SHISA2, SCARA5, LHX2, RORC, DPYSL4, CH25H, and CHST1 in a sample and determining the differential activity of the one or more genes relative to a control; correlating the differential activity of the one or more genes relative to the control to obtain a p-score; and determining the type of fibroepithelial tumour based on the p-score, wherein a p-score of less than 0.5 is indicative of a fibroadenoma and a p-score of 0.5 and above is indicative of phyllodes tumour. Particularly, the said method is exemplified using an expression profile of five genes comprising of PRAME, FN1, CCL19, ABCA8 and APOD. A method for managing the treatment of a subject with a fibroepithelial tumour of the breast is also provided as well as a kit when used in the methods of the present invention.

The invention discloses a combined marker for early diagnosis of liver cancer and its application. The combined markers for early diagnosis of liver cancer disclosed in the present invention are FAM78A, MKL1, DCDC2, SR, BCL2L11, CYP1B1, PTPN7, AXIN1, SEMA4D, PROX1, SHH, AK055957, DAB2IP, TBX15, GRASP, PPFIA1 and / or PSD4. Methylation, and mutation of TERT and / or CTNNB1. The present invention performs liver cancer detection by detecting the methylation level of the gene combination in the plasma cfDNA, and has high sensitivity and specificity; in the case of adding the mutation detection of the gene, by simultaneously detecting the methylation of the gene combination and the TERT gene , CTNNB1 gene mutation, effectively improve the sensitivity of early screening.